###### Strengths and limitations of this study

-   To our knowledge, this is the first systematic review that formally analyses and compares the diagnostic accuracy of currently available point-of-care tests for urinary tract infections (UTIs) diagnosis.

-   The results from this study will help identify the best available point-of-care test to diagnose UTIs in the primary care setting.

-   It is likely that significant heterogeneity will be found as all available tests will be explored, and meta-analysis will be performed to account for this.

-   Studies involving paediatric population (\<18 years old) or populations with certain conditions (detailed in exclusion criteria) will be excluded, as well as studies aimed at screening of asymptomatic bacteriuria, which may affect the generalisability of the results out with these situations.

Introduction {#s1}
============

Urinary tract infections (UTIs) are the second most common cause of infection in primary[@R1] and secondary care[@R2] and most women experience at least one episode of acute uncomplicated cystitis in their lifetime. In the UK, UTIs account for 1%--3% of all consultations in primary care each year.[@R1] UTIs are also responsible for a major part of antibiotic prescriptions, accounting for up to 15% of antimicrobial use in the community, with antibiotic use been described as one of the main factors contributing to the emergence of antimicrobial resistance (AMR).[@R3] The rise of AMR has been postulated as one of the major challenges for healthcare worldwide.[@R4] It is related to increased morbidity, mortality and cost, particularly in vulnerable populations such as the elderly.[@R4] The WHO Global Action Plan to Reduce Antimicrobial Resistance[@R5] includes improving antimicrobial use across all human and animal health, and environment settings through a One Health approach. Rates of AMR among gram-negative bacteria have progressively increased in the last decade in the European Union (EU),[@R6] with particularly concerning rise of carbapenemase-producing and extended-spectrum-beta-lactamase organisms.[@R7]

Currently, most clinical guidelines recommend that primary care diagnosis and management of uncomplicated UTI should be done empirically,[@R8] thus based on clinical symptoms. Although this approach has proven to be cost effective,[@R10] prescribing without diagnostic certainty increases the use of potentially unnecessary antibiotics, and contributes to the problem of AMR.[@R11] Up to 90% of patients presenting to primary care with urinary symptoms receive an antibiotic[@R7] but it is usually without further investigation, so it is unclear how many will have a proven infection. Available evidence on how well symptoms predict the presence of a true UTI has shown diverging results, when compared with gold standard (urine culture). The probability of a female patient presenting to primary care with typical UTI symptoms and having a confirmed infection is estimated to be between 50%--80%, with the greatest predictability for haematuria, and if combined with a positive urine dipstick.[@R13] Therefore, alternative tests with enhanced diagnostic accuracy could potentially reduce inappropriate antimicrobial use in this context.

The gold standard for UTI diagnosis is urine culture from a midstream, clean urine catch, but as previously mentioned, urine culture is not always performed, especially in primary care and emergency departments, where diagnosis of most UTIs occurs.[@R15] Urine culture is slow, requiring at least 24--48 hours to report the causative microorganism and provide an antibiotic resistance profile,[@R16] and symptoms are usually distressing enough to prompt on the day empirical management, since acutely unwell patients with UTI symptoms may not be prepared to wait up to 48 hours for a culture result. Current clinical guidelines also advocate empirical treatment if symptoms are sufficiently suggestive of a diagnosis of UTI.[@R9] Empirical decision-making will often result in the patient getting an antibiotic without infection confirmation. As result of this, different point-of-care tests (POCT) have been developed aiming to provide a more rapid and accurate method for detecting infection. POCT has been defined as 'a test to support clinical decision making, performed nearby the patient and on any part of the patient's body or its derivates, to help the patient and healthcare professional on the best management approach during or very close to the time of the consultation, with results available at the time of clinical decision making'.[@R17] POCT diagnostic accuracy is influenced dramatically from pretest probability in different subpopulations[@R18] and consequently, its ability to detect or discard infection can be variable.[@R19] Potentially, an 'ideal' POCT would allow for more timely identification of UTIs, facilitating improved, targeted treatment, and reduced inappropriate antibiotic use. Indirect methods, such as urine dipsticks, which detect host inflammatory response rather than bacterial presence, have become the main POCT for UTIs.[@R21] Other techniques include culture-based devices, enzymatic assays and semiautomated urine analysers.[@R22] Previous reports suggest that their diagnostic accuracy could be greater than that of simpler urine dipsticks.[@R16] These tests could provide relevant information to clinicians to prescribe antimicrobials more accurately, reducing antibiotic-related harms (including resistance), and costs.[@R23] However, it is difficult to ascertain which POCT could be better for diagnosing UTIs, in general, and in specific situations.

Our aim is to systematically review and meta-analyse the diagnostic test accuracy of currently available POCTs for UTIs, as compared with gold standard (urine culture).

Methods and analysis {#s2}
====================

Eligibility criteria {#s2-1}
--------------------

Randomised clinical trials (RCTs), cluster RCTs, evaluation studies, observational studies and regulatory or approval evidence reports (if available), evaluating point-of-care diagnostic tests for UTI in symptomatic patients versus urine culture (reference standard)[@R7] will be included, from both primary or secondary care settings. No particular index test was prespecified in our review search criteria, as we aimed to capture and compare all available tests. However, only those tests that could be categorised as 'point-of-care test' will be included, defined as above.[@R17] Inclusion criteria are detailed in [table 1](#T1){ref-type="table"}, following the PIRD (Participants, Index test, Target condition, Reference standard) approach for including studies in systematic reviews of diagnostic test accuracy.[@R24]

###### 

Inclusion criteria

  --------------------- --------------------------------------------
  Participants:         Adults
  Presentation:         Symptomatic UTIs (variously defined)[@R13]
  Index test(s):        Any point-of-care diagnostic test
  Target condition:     Urinary tract infections
  Reference standard:   Urine culture
  --------------------- --------------------------------------------

UTIs, urinary tract infections.

The search strategy uses broad terms for defining UTI with the aim of capturing all potentially relevant studies looking at POCT used in symptomatic UTIs. Classical symptoms include those mentioned in [table 1](#T1){ref-type="table"}, and we will also examine different symptoms/combinations and UTI definition used in each study. Exclusion criteria will be applied and are detailed below. These include:

-   Studies evaluating the detection of asymptomatic bacteriuria in pregnancy.

-   Studies performed only in children.

-   Tests aimed at detecting sexually transmitted infections, or non-bacterial infections (eg, schistosomiasis).

-   Tests based on biomarkers needing laboratory facilities.

-   Studies whose main outcome measure is to detect complications of urinary infections (eg, CT scans or other imaging techniques).

-   Clinical algorithms or self-reported symptom tests.

-   Specific populations will be excluded: urinary catheterised patients, kidney transplantation, terminal kidney failure or immunocompromised patients, patients with spinal cord injury or neurogenic bladder.

Information sources and search {#s2-2}
------------------------------

Medline, Web of Science, Embase and Cochrane Database of Systematic Reviews were searched from database inception to 1 June 2019 with no language restrictions. Only studies involving human health were included. The search included a combination of the following terms: "Urinary Tract Infections/diagnosis", "Diagnostic Tests, Routine", "Point-of-Care Systems", "Point-of-Care Testing", "point-of-care testing", 'near-patient testing', 'RDT', "poct", "Diagnostic Technics and Procedures", "Techni\* and Procedures, Diagnostic", "rapid diagnostic test\*", AND "Urinary Tract Infections", "Pyuria", "Bacteriuria", "uti", AND "sensitivity", "specificity", "likelihood ratio", "predictive value", "diagnostic accuracy", "AUC", "PPV", "NPV", among other. The full search strategy is available in [online supplementary appendix 1](#SP1){ref-type="supplementary-material"} and online in PROSPERO's database.[@R25]
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Data management {#s2-3}
---------------

Search results will be stored in EndNote V.X8.2 bibliography management software. To synthetise and develop study selection, data extraction and quality assessment, we will use Covidence platform.[@R26]

Study selection {#s2-4}
---------------

Three reviewers (DFN, AAL and VHS) will independently assess study eligibility for inclusion. A calibration exercise assessing 10% of the results by title and abstract will be done in duplicate. After title and abstract screening, selected articles will be screened full text. Discrepancies will be solved by discussion. Another reviewer will be involved as necessary (FS).

Data collection process {#s2-5}
-----------------------

A standardised data extraction form will be developed. The review team (DFN, AAL and VHS) will independently extract the data from all studies. Study authors will be contacted if no data are available. All articles will be double extracted, and risk of bias will be double assessed. Discrepancies will be evaluated and solved by discussion, and if no agreement, a third reviewer will be involved.

Diagnostic accuracy measures {#s2-6}
----------------------------

A 2×2 contingency table with true positives, true negatives, false positives and false negatives will be extracted from each study. Accuracy outcome measures will include: sensitivity, specificity, positive and negative predictive values.

Definitions for data extraction {#s2-7}
-------------------------------

From each study, besides the accuracy-related data already specified, we will extract the following predefined set of characteristics:

-   Device/product name.

-   Manufacturer/country of origin.

-   Regulatory approval status in the EU and USA.

-   Type of sample used (clean urine midstream catch, or other).

-   Method principle (culture-based, enzymatic assay, other).

-   Analysis time (time required, in minutes).

-   Additional training required.

-   Need for supplementary equipment (eg, steriliser, centrifuge, etc).

-   Cost.

-   Type of result provided if the test is positive (presence of infection, bacterial load, antibiotic sensitivity, indirect method for detection).

-   The threshold for positivity detection, in unit forming colonies.

-   Population tested.

-   UTI definition used.

-   Secondary outcomes: mortality, hospitalisation, quality of life measures and/or patients' preferences, if reported.

Risk of bias {#s2-8}
------------

Methodological quality assessment will be conducted using the Quality Assessment of Diagnostic Accuracy Studies tool.[@R27]

Synthesis of results {#s2-9}
--------------------

A narrative description summarising the prespecified characteristics of each test, and a paired sensitivity--specificity forest plot, will be provided. Meta-analysis will be performed depending on available data, sources of heterogeneity, comparability between methods and ability to aggregate data. If enough data are available, random-effect meta-analysis will be performed for each index test. The bivariate model will be used to ascertain summary sensitivity and specificity if all studies in the group use the same threshold value for positivity. If index tests use different threshold values, the hierarchical summary receiver operating characteristic (HSROC)model will be used instead, to obtain summary sensitivity and specificity for each threshold value. Sources of heterogeneity will be investigated, regarding index test used, threshold for detection, target population included in the study and its given (if reported) pretest probability. Subgroup analysis will be explored and performed depending on the heterogeneity found and available data, analysing separately studies looking at each POCT and also different population groups (differentiating adults from elderly patients).

Patients and public involvement {#s2-10}
-------------------------------

Patients or the public were not involved in the design of our research. However, the findings from this review will be shared with key stakeholders, including patient groups, clinicians and guideline developers, and will also be presented and national and international conferences.

Ethics and dissemination {#s3}
========================

Ethical approval was explored with the University of St Andrews School of Medicine Research and Ethics Committee but was not necessary due to the nature of the research (literature review). Results from this review will be shared with key stakeholders, including patient groups, clinicians and guideline developers, and will potentially inform future diagnostic and treatment pathways.

Supplementary Material
======================
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